Sat.Jul 13, 2024 - Fri.Jul 19, 2024

article thumbnail

Digital Health’s Funding Rebound Is Going Well, Market Research Shows

MedCity News

The digital health fundraising market seems to be truly normalizing following the highs and lows of the pandemic, according to market research. During the first half of this year, U.S. digital health startups raked in $5.7 billion across 266 deals. The post Digital Health’s Funding Rebound Is Going Well, Market Research Shows appeared first on MedCity News.

Marketing 116
article thumbnail

Amgen, BMS and Merck have the most exposure as Big Pharma eyes $183B patent cliff: analyst

Fierce Pharma

While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note f | While patent cliffs loom for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a July 11 research note from Morgan Stanley.

Pharma 348
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CCC Pioneers Collective Licensing Solution for Content Usage in Internal AI Systems

Copyright Clearance Center

July 16, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced the availability of artificial intelligence (AI) re-use rights within its Annual Copyright License s (ACL), an enterprise-wide content licensing solution offering rights from millions of works to businesses that subscribe.

Education 134
article thumbnail

Endo Recalls Clonazepam Because of Mislabeling

PharmaTech

The company has issued a voluntary recall of one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV), because of incorrect strength published on product carton.

118
118
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

The FTC Released a Scathing Interim Report on PBMs. What’s Next?

MedCity News

The Federal Trade Commission recently released an interim report that details how the practices of pharmacy benefit managers negatively impact patients and pharmacies. Some experts hope for legislative action based on the report. The post The FTC Released a Scathing Interim Report on PBMs. What’s Next? appeared first on MedCity News.

article thumbnail

FDA proposes cell and gene therapy site tours to help regulators learn from industry

Fierce Pharma

It's no secret that cell and gene therapies have faced manufacturing hurdles as the advanced medicines have become increasingly popular in recent years. | It's no secret that cell and gene therapies have faced manufacturing hurdles as the advanced medicines have become increasingly popular in recent years. Now, the FDA is proposing to work directly with industry through a series of facility tours that could enable both sides to learn something from each other.

FDA 326

More Trending

article thumbnail

Susvimo Demonstrates Sustained Efficacy Over Two Years in Patients with Diabetic Macular Edema and Diabetic Retinopathy

Pharmaceutical Commerce

FDA to review one-year results for Susvimo showing non-inferior visual acuity gains in diabetic macular edema and in the Diabetic Retinopathy Severity Scale for Diabetic Retinopathy.

FDA 104
article thumbnail

The Shifting AI Landscape

MedCity News

A new eBook from MedCity News highlights the variety of technologies emerging from AI tech developers across the healthcare landscape from health tech startups to healthcare organizations, biopharma companies, and a medtech giant. It also explores the ethical issues AI in healthcare presents. The post The Shifting AI Landscape appeared first on MedCity News.

Ethics 113
article thumbnail

Pfizer's ATTR heart disease drug needs hefty discount, says ICER draft report. What about Alnylam's Amvuttra?

Fierce Pharma

Pfizer’s blockbuster drug tafamidis for the treatment of the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) needs at least a 96% discount off its list price to be considered cost | Pfizer’s blockbuster tafamidis for the treatment of the rare heart disease ATTR-CM needs at least a 96% discount off its list price to be considered cost-effective under common benchmarks, a draft report by ICER has found.

316
316
article thumbnail

FDA launches innovation hub to spur rare disease R&D

pharmaphorum

FDA will create a rare disease hub to speed the development of new treatments and build connections between developers and the rare disease community

FDA 116
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

European Pharmacopoeia makes milestone pyrogen testing commitment

European Pharmaceutical Review

European Pharmacopoeia has confirmed it will remove the rabbit pyrogen test (RPT) from its monographs. This milestone decision was made during the Ph. Eur.’s 179th session in June 2024. The RPT has been the traditional detection method for pyrogens, the European Directorate for the Quality Of Medicines (EDQM) explained. In June 2021, the European Pharmacopoeia Commission (EPC) committed to completely replace the RPT in the 59 Ph.

article thumbnail

Tau-Focused Asceneuron Adds $100M as Oral Alzheimer’s Drug Advances to Phase 2 Trial

MedCity News

Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative disorders. The post Tau-Focused Asceneuron Adds $100M as Oral Alzheimer’s Drug Advances to Phase 2 Trial appeared first on MedCity News.

Leads 113
article thumbnail

J&J, BMS and AstraZeneca strike back in appeals after IRA litigation losses

Fierce Pharma

Despite a string of high-profile losses this year, at least three major drugmakers continue to fight back against the Medicare price negotiations being rolled out under the Inflation Reduction Act. | Despite a string of high-profile losses this year, at least three major drugmakers continue to fight back against the Medicare price negotiations being rolled out under the Inflation Reduction Act.

290
290
article thumbnail

CCC Launches Collective Licensing for AI

Copyright Clearance Center

Copyright Clearance Center has launched a collective licensing solution for the internal use of copyrighted materials in artificial intelligence systems, with the aim of providing streamlined, legal means to use content and compensate creators.

98
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Has pharma emerged from the ‘age of uncertainty’?

PharmaVoice

An industry reeling from a precarious market is showing signs of stabilizing as the future becomes a little less cloudy, an Evaluate report suggests.

Pharma 106
article thumbnail

Report: Cost Reduction Is Less of a Priority for Health CFOs Compared to Past Years

MedCity News

Cost reduction is no longer a top priority for healthcare finance leaders, a new Deloitte survey found. In past years, cost reduction was among the top three priorities. The post Report: Cost Reduction Is Less of a Priority for Health CFOs Compared to Past Years appeared first on MedCity News.

article thumbnail

J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer

Fierce Pharma

CAR-T specialist Legend Biotech has reportedly received a takeover bid and has tapped Centerview Partners as a financial adviser to evaluate its options, StreetInsider

296
296
article thumbnail

J&J IRA pricing offer is in, as it sticks with 2025 guidance

pharmaphorum

J&J has three of its top-selling drugs in Medicare pricing negotiations but does not expect a major hit to its finances next year

112
112
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

FDA launches new rare disease innovation hub

Pharmaceutical Technology

The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.

FDA 111
article thumbnail

What Does It Take to Move an Entire Hospital in 1 Day? Intermountain Health Is About to Find Out

MedCity News

For the past two years, Intermountain Health has been planning to move its hospital in the Denver suburb of Wheat Ridge, Colorado about three and a half miles away to a new and updated facility. The health system is planning to complete the move in one day, using about 20 ambulances to move an estimated 180 patients. The post What Does It Take to Move an Entire Hospital in 1 Day?

Patients 108
article thumbnail

GSK moves back to its roots with new central London headquarters

Fierce Pharma

After two decades headquartered in the West London suburb of Brentford, GSK is officially coming home to central London. | After two decades headquartered in the West London suburb of Brentford, GSK's new digs are officially open and will house 3,000 workers in London's Knowledge Quarter.

291
291
article thumbnail

Ozempic’s latest health benefit may be cutting dementia risk

pharmaphorum

Observational study finds lower risk of cognitive problems and nicotine dependence in diabetics using Novo Nordisk's Ozempic

114
114
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

The US Biosecure Act threatens to destabilise the pharmaceutical industry 

Pharmaceutical Technology

In January, the US House Select Committee on the Strategic Competition between the US and the Chinese Communist Party introduced the Biosecure Act.

article thumbnail

What the Medicare Quality Rating Change Means for Healthcare Companies — and Patient Health

MedCity News

SMS is reevaluating its Star Ratings. Not only do health plans stand to benefit from the new calculations — all healthcare companies and millions of patients will reap the rewards. The post What the Medicare Quality Rating Change Means for Healthcare Companies — and Patient Health appeared first on MedCity News.

article thumbnail

Bayer’s Nubeqa, en route to blockbusterland, clinches 2nd win in prostate cancer subtype

Fierce Pharma

Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer (mHSPC). | Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer.

283
283
article thumbnail

Cardurion heads crop of sizeable bio financings

pharmaphorum

While the pace of biotech private rounds seems to have slowed a little of late, this week saw four big financings for Cardurion Pharma, Scorpion Therapeutics, CatalYm, and NGM Bio.Burlington, Massachusetts-based Cardurion led the quartet with a $260 million Series B for its heart-focused drug pipeline, which features two candidates in phase 2 testing – PDE9 inhibitor CRD-750 for heart failure and CaMKII inhibitor CRD-4730 for rare genetic disease catecholaminergic polymorphic ventricular tachyca

Pharma 93
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

CCC Announces a Collective Licensing Subscription for AI Systems

Copyright Clearance Center

Copyright Clearance Center's AI re-use rights offer stands in its Annual Copyright Licenses subscription program for 'millions of works.

98
article thumbnail

Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug

MedCity News

Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 billion acquisition of Carmot Therapeutics last year. The post Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug appeared first on MedCity News.

Biopharma 107
article thumbnail

Johnson & Johnson proposes $505M settlement with bankrupt talc miners

Fierce Pharma

As Johnson & Johnson continues to attempt to Texas two-step its way around thousands of claims that its popular talcum powder-based products caused cancer, the drugmaker is putting up hundreds | As Johnson & Johson continues to attempt to Texas two-step its way around thousands of claims that its popular talcum powder-based products caused cancer, the drugmaker is putting up hundreds of millions of dollars to settle a longstanding dispute with a clutch of suppliers.

272
272
article thumbnail

Boehringer backs Brainomix AI software for lung fibrosis

pharmaphorum

Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases

102
102
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time